BYD confirms AI robot Xiao Di as US hits the brakes immediately

Xiao-I Corporation (NASDAQ: AIXI) said Shanghai High People’s Court issued June 10, 2026 first-instance rulings in its patent dispute with Apple over Siri. The court dismissed Xiao-I’s infringement claims for its “A Chat Robot System” patent (No. 200410053749.9) and found specified iPhone models with Siri outside the patent scope, rejecting Apple’s RMB 2 million litigation-expense request. Xiao-I plans to appeal to China’s Supreme People’s Court.

XIAO-I Corporation’s unsponsored ADR (NASDAQ:AIXI) saw a sharp May decline in short interest, falling to 267,960 shares as of May 15 from 5,939,944 on April 30, a 95.5% drop, according to the article. With average volume of 316,542 shares, the short-interest ratio is 0.8 days; about 29.1% of shares are sold short. The stock traded down 5.4% to $13.62 midday.

Taiwan indicted nine people, including an Nvidia manager, for illegally exporting 130 AI servers to China. Prosecutors allege the Nvidia employee certified a fraudulent inspection. Nvidia and Super Micro, whose products were involved, are cooperating with the investigation. The B300 servers are restricted for export to China due to their dual-use capabilities. The scheme involved fake documentation and routing through intermediaries, with proceeds totaling approximately $21.2 million. (350 chara

Ultragenyx Pharmaceutical's Genglycos, a gene therapy for glycogen storage disease type Ia, received FDA accelerated approval on August 19, 2026. Approval was based on reduced cornstarch intake, not hypoglycemia prevention. The therapy showed a 3% increase in hypoglycemic readings. Safety concerns include immune-mediated liver enzyme elevations and adrenal insufficiency. The company's ticker is RARE.

The FDA approved Johnson & Johnson's drug Imaavy for treating warm autoimmune hemolytic anemia in patients aged 12+. The approval covers those treated with steroids and is based on a study showing improved hemoglobin levels. Imaavy blocks harmful antibodies and is infused every four weeks. Common side effects include swelling, diarrhea, and fever. According to the company, the drug offers important advances for patients.

The SEC has subpoenaed Goldman Sachs, JPMorgan, Citigroup, and Bank of America regarding their ties to AI hedge fund Situational Awareness, which faced losses in July. The regulator seeks details on the fund's trades and communications with the banks, per the New York Times.